Risk for immune-mediated graft dysfunction in liver transplant recipients with recurrent HCV infection treated with pegylated interferon.

PubWeight™: 1.01‹?› | Rank: Top 15%

🔗 View Article (PMID 22285805)

Published in Gastroenterology on January 25, 2012

Authors

Josh Levitsky1, Maria Isabel Fiel, John P Norvell, Edward Wang, Kymberly D Watt, Michael P Curry, Sumeet Tewani, Timothy M McCashland, Maarouf A Hoteit, Abraham Shaked, Samuel Saab, Amanda C Chi, Amy Tien, Thomas D Schiano

Author Affiliations

1: Northwestern University Feinberg School of Medicine, Northwestern Memorial Hospital, Chicago, Illinois 60611, USA. j-levitsky@northwestern.edu

Articles citing this

Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. Liver Transpl (2012) 1.05

Drug-drug interactions with oral anti-HCV agents and idiosyncratic hepatotoxicity in the liver transplant setting. J Hepatol (2013) 1.01

Changing the face of hepatitis C management - the design and development of sofosbuvir. Drug Des Devel Ther (2015) 0.93

Recurrence of hepatitis C after liver transplantation. Ann Gastroenterol (2013) 0.88

Sofosbuvir and Simeprevir for the Treatment of Recurrent Hepatitis C with Fibrosing Cholestatic Hepatitis after Liver Transplantation. Int J Organ Transplant Med (2016) 0.82

Recurrent hepatitis C after liver transplant. World J Gastroenterol (2014) 0.79

Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection. World J Gastroenterol (2016) 0.78

Recurrent hepatitis C virus after transplant and the importance of plasma cells on biopsy. World J Gastroenterol (2013) 0.77

Histopathological evaluation of recurrent hepatitis C after liver transplantation: a review. World J Gastroenterol (2014) 0.77

Immunological dysfunction during or after antiviral therapy for recurrent hepatitis C reduces graft survival. Hepatol Int (2013) 0.76

Routine Laboratory Blood Tests May Diagnose Significant Fibrosis in Liver Transplant Recipients with Chronic Hepatitis C: A 10 Year Experience. J Clin Transl Hepatol (2016) 0.75

Hepatitis C Recurrence after Orthotopic Liver Transplantation: Mechanisms and Management. J Clin Transl Hepatol (2014) 0.75

Curing Hepatitis C in Liver Transplant Recipients Is Associated with Changes in Immunosuppressant Use. J Clin Transl Hepatol (2016) 0.75

De novo autoimmune hepatitis in liver transplant: State-of-the-art review. World J Gastroenterol (2016) 0.75

Intravenous interferon administered during liver transplantation is not effective in preventing hepatitis C reinfection. Dig Dis Sci (2013) 0.75

Articles by these authors

Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med (2002) 11.38

Urinary-cell mRNA profile and acute cellular rejection in kidney allografts. N Engl J Med (2013) 7.40

Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria. Science (2012) 4.20

Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology (2011) 3.57

Functional restoration of HCV-specific CD8 T cells by PD-1 blockade is defined by PD-1 expression and compartmentalization. Gastroenterology (2008) 2.95

Methotrexate (MTX) plus ursodeoxycholic acid (UDCA) in the treatment of primary biliary cirrhosis. Hepatology (2005) 2.91

Informing candidates for solid-organ transplantation about donor risk factors. N Engl J Med (2008) 2.83

Pediatric nurses' beliefs and pain management practices: an intervention pilot. West J Nurs Res (2010) 2.73

Improvement in survival associated with adult-to-adult living donor liver transplantation. Gastroenterology (2007) 2.72

Measuring the significance of field validation in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology: how good are the experts? Arch Pathol Lab Med (2005) 2.69

Liver transplantation from controlled non-heart-beating donors: an increased incidence of biliary complications. Transplantation (2003) 2.63

Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathog (2009) 2.57

Physical activity participation among persons with disabilities: barriers and facilitators. Am J Prev Med (2004) 2.48

Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology (2010) 2.35

Autologous options for postmastectomy breast reconstruction: a comparison of outcomes based on the American College of Surgeons National Surgical Quality Improvement Program. J Am Coll Surg (2012) 2.20

State of the art in trueness and interlaboratory harmonization for 10 analytes in general clinical chemistry. Arch Pathol Lab Med (2008) 2.15

Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. Lancet (2012) 2.13

Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues. Gastroenterology (2012) 2.11

Increased prevalence of primary biliary cirrhosis near Superfund toxic waste sites. Hepatology (2006) 2.08

TIPS for refractory ascites: a 6-year single-center experience with expanded polytetrafluoroethylene-covered stent-grafts. AJR Am J Roentgenol (2015) 1.99

Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl (2004) 1.95

A comprehensive risk assessment of mortality following donation after cardiac death liver transplant - an analysis of the national registry. J Hepatol (2011) 1.94

Renal function after orthotopic liver transplantation is predicted by duration of pretransplantation creatinine elevation. Liver Transpl (2005) 1.87

Applying multimedia design principles enhances learning in medical education. Med Educ (2011) 1.80

Creatinine measurement: state of the art in accuracy and interlaboratory harmonization. Arch Pathol Lab Med (2005) 1.77

Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. Liver Transpl (2007) 1.76

Lack of benefit of pre-transplant locoregional hepatic therapy for hepatocellular cancer in the current MELD era. Liver Transpl (2006) 1.72

Posttransplant plasma cell hepatitis (de novo autoimmune hepatitis) is a variant of rejection and may lead to a negative outcome in patients with hepatitis C virus. Liver Transpl (2008) 1.68

Endoscopic management of biliary complications after adult living donor liver transplantation. Am J Gastroenterol (2004) 1.68

Use of physician education and computer alert to improve targeted use of gastroprotection among NSAID users. Am J Gastroenterol (2008) 1.67

Aurora B kinase phosphorylates and instigates degradation of p53. Proc Natl Acad Sci U S A (2012) 1.66

Oral antibiotic prophylaxis reduces spontaneous bacterial peritonitis occurrence and improves short-term survival in cirrhosis: a meta-analysis. Am J Gastroenterol (2009) 1.62

Osteopontin binding to lipopolysaccharide lowers tumor necrosis factor-α and prevents early alcohol-induced liver injury in mice. Hepatology (2014) 1.62

Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody-positive donors: a systematic review. Liver Transpl (2010) 1.61

Survival and risk of recidivism in methadone-dependent patients undergoing liver transplantation. Am J Transplant (2003) 1.60

Racial variation in colorectal polyp and tumor location. J Natl Med Assoc (2007) 1.60

Beta-adrenoceptor agonists stimulate endothelial nitric oxide synthase in rat urinary bladder urothelial cells. J Neurosci (2002) 1.58

Transplantation: impact of pretransplant renal insufficiency. Liver Transpl (2008) 1.58

Barriers associated with exercise and community access for individuals with stroke. J Rehabil Res Dev (2008) 1.57

Distribution of the tight junction proteins ZO-1, occludin, and claudin-4, -8, and -12 in bladder epithelium. Am J Physiol Renal Physiol (2004) 1.57

Validation of a current definition of early allograft dysfunction in liver transplant recipients and analysis of risk factors. Liver Transpl (2010) 1.56

Stretch-regulated exocytosis/endocytosis in bladder umbrella cells. Mol Biol Cell (2002) 1.56

Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort. Radiology (2010) 1.55

Resident involvement and plastic surgery outcomes: an analysis of 10,356 patients from the American College of Surgeons National Surgical Quality Improvement Program database. Plast Reconstr Surg (2013) 1.54

Poor survival after liver retransplantation: is hepatitis C to blame? Liver Transpl (2003) 1.52

Outcomes of patients with hepatitis C undergoing simultaneous liver-kidney transplantation. J Hepatol (2009) 1.50

Demographic, psychosocial, and behavioral factors associated with survival after heart transplantation. Ann Thorac Surg (2013) 1.48

Crosstalk between mast cells and pancreatic cancer cells contributes to pancreatic tumor progression. Clin Cancer Res (2010) 1.46

De novo hepatocellular carcinoma occurring in a transplanted liver: case report and review of the literature. Dig Dis Sci (2006) 1.45

Relevance of the c-statistic when evaluating risk-adjustment models in surgery. J Am Coll Surg (2012) 1.45

Diabetes mellitus and advanced liver fibrosis are risk factors for severe anaemia during telaprevir-based triple therapy. Liver Int (2013) 1.43

Phenytoin overview--metabolite interference in some immunoassays could be clinically important: results of a College of American Pathologists study. Arch Pathol Lab Med (2003) 1.41

Osteopontin, an oxidant stress sensitive cytokine, up-regulates collagen-I via integrin α(V)β(3) engagement and PI3K/pAkt/NFκB signaling. Hepatology (2012) 1.40

Sequential presentation of primary biliary cirrhosis and autoimmune hepatitis. Eur J Gastroenterol Hepatol (2014) 1.40

Ascites after liver transplantation--a mystery. Liver Transpl (2004) 1.40

The impact of ischemic cholangiopathy in liver transplantation using donors after cardiac death: the untold story. Surgery (2009) 1.39

Interferon alpha 2b and ribavirin for the treatment of recurrent hepatitis C after liver transplantation: cohort study of 38 patients. J Gastroenterol Hepatol (2005) 1.39

Prevalence of hepatic iron overload and association with hepatocellular cancer in end-stage liver disease: results from the National Hemochromatosis Transplant Registry. Liver Int (2007) 1.30

Radiographic response to locoregional therapy in hepatocellular carcinoma predicts patient survival times. Gastroenterology (2011) 1.25

Dendritic cell regulation of carbon tetrachloride-induced murine liver fibrosis regression. Hepatology (2012) 1.24

Inoculation against falls: rapid adaptation by young and older adults to slips during daily activities. Arch Phys Med Rehabil (2010) 1.24

Autoimmune hepatitis: a review of current diagnosis and treatment. Hepat Res Treat (2011) 1.24

Biliary casts after orthotopic liver transplantation: clinical factors, treatment, biochemical analysis. Am J Gastroenterol (2003) 1.23

Interleukin-6 from intrahepatic cells of bone marrow origin is required for normal murine liver regeneration. Hepatology (2002) 1.23

Decrease in hepatic CD56(+) T cells and V alpha 24(+) natural killer T cells in chronic hepatitis C viral infection. J Hepatol (2002) 1.22

Recruitment of African American women to a walking program: eligibility, ineligibility, and attrition during screening. Res Nurs Health (2006) 1.21

Allograft survival following adult-to-adult living donor liver transplantation. Am J Transplant (2004) 1.20

Summary report of a national conference: Evolving concepts in liver allocation in the MELD and PELD era. December 8, 2003, Washington, DC, USA. Liver Transpl (2004) 1.19

Laparoscopic-assisted vs. open colectomy for cancer: comparison of short-term outcomes from 121 hospitals. J Gastrointest Surg (2008) 1.18

Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer. Mol Cancer (2010) 1.15

Neighborhood environment and adherence to a walking intervention in African American women. Health Educ Behav (2008) 1.14

Accessibility of health clubs for people with mobility disabilities and visual impairments. Am J Public Health (2005) 1.13

The presence of JAK2V617F mutation in the liver endothelial cells of patients with Budd-Chiari syndrome. Blood (2009) 1.13

Hospitalization rates before and after adult-to-adult living donor or deceased donor liver transplantation. Ann Surg (2010) 1.13

A randomized, open-label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients. Liver Transpl (2005) 1.13

Superior survival using living donors and donor-recipient matching using a novel living donor risk index. Hepatology (2014) 1.12

Obesity prevalence among a group of Chicago residents with disabilities. Arch Phys Med Rehabil (2005) 1.11

Ischemic cholangiopathy after controlled donation after cardiac death liver transplantation: a meta-analysis. Ann Surg (2011) 1.11

A multicenter evaluation of safety of early extubation in liver transplant recipients. Liver Transpl (2007) 1.10

Outcomes of a home-based walking program for African-American women. Am J Health Promot (2008) 1.09

Comparative effectiveness of donation after cardiac death versus donation after brain death liver transplantation: Recognizing who can benefit. Liver Transpl (2012) 1.08

The course of posttransplant hepatitis C infection: comparative impact of donor and recipient source of the favorable IL28B genotype and other variables. Transplantation (2012) 1.08

Early and late outcome of cardiac surgery in patients with liver cirrhosis. Liver Transpl (2007) 1.08

Burden of de novo malignancy in the liver transplant recipient. Liver Transpl (2012) 1.07

Women's health issues with fibromyalgia syndrome. J Womens Health (Larchmt) (2006) 1.06

The human "Treg MLR": immune monitoring for FOXP3+ T regulatory cell generation. Transplantation (2009) 1.06

Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response. Hepatology (2014) 1.05

Lack of specificity of cyclosporine immunoassays. Results of a College of American Pathologists Study. Arch Pathol Lab Med (2003) 1.04

Analytic bias of thyroid function tests: analysis of a College of American Pathologists fresh frozen serum pool by 3900 clinical laboratories. Arch Pathol Lab Med (2005) 1.04

Menopausal status, moderate-intensity walking, and symptoms in midlife women. Res Theory Nurs Pract (2005) 1.03

Prevalence of nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Clin Gastroenterol Hepatol (2007) 1.03

T cell targeting and phagocytosis of apoptotic biliary epithelial cells in primary biliary cirrhosis. J Autoimmun (2007) 1.03

Prospective measurements of intra-abdominal volume and pulmonary function after repair of massive ventral hernias with the components separation technique. Ann Surg (2010) 0.99

Aerobic exercise training in stroke survivors. Top Stroke Rehabil (2005) 0.99

Teaching for understanding in medical classrooms using multimedia design principles. Med Educ (2013) 0.99

Antifibrotic activity of sorafenib in experimental hepatic fibrosis: refinement of inhibitory targets, dosing, and window of efficacy in vivo. Dig Dis Sci (2012) 0.98

Isolated gastrocnemius and soleal vein thrombosis: should these patients receive therapeutic anticoagulation? Ann Surg (2010) 0.98

The outcome of liver grafts procured from hepatitis C-positive donors. Transplantation (2002) 0.98

Effects of perceived and objective neighborhood crime on walking frequency among midlife African American women in a home-based walking intervention. J Phys Act Health (2010) 0.97